GlycA is not a useful biomarker of inflammation in sickle cell disease
| Autor: | Darlene Allen, Arun S. Shet, Julie K. Weisman, Daveena Meeks, Swee Lay Thein, Alan T. Remaley, Maureen Sampson, Laurel Mendelsohn, Jim Nichols |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Glycation End Products Advanced Male 0301 basic medicine medicine.medical_specialty Clinical Biochemistry Cell Recurrent inflammation Inflammation Anemia Sickle Cell Disease Gastroenterology Article 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans Nuclear Magnetic Resonance Biomolecular GlycA biology business.industry Biochemistry (medical) Haptoglobin Hematology General Medicine Middle Aged medicine.disease Blood proteins Hemolysis 030104 developmental biology medicine.anatomical_structure 030220 oncology & carcinogenesis biology.protein biomarker Biomarker (medicine) sickle cell disease Female hemolysis medicine.symptom business Biomarkers |
| Zdroj: | International journal of laboratory hematology |
| ISSN: | 1751-5521 |
| DOI: | 10.1111/ijlh.12907 |
| Popis: | Introduction: Sickle cell disease (SCD) is a multisystemic disorder, the pathology being driven by recurrent inflammation particularly during a vaso-occlusive crisis. GlycA, a composite measure of protein glycation, is a sensitive biomarker for disorders associated with vascular inflammation. We determined the utility of GlycA as a biomarker of inflammation in SCD. Methods: Stored plasma samples from patients with SCD recruited to two clinical studies were analyzed. One study encompasses 488 patient samples with SCD (HbSS, HbSβ0 and HbSC) at steady state and 52 race-matched, healthy controls. The other study included paired plasma samples during steady state and acute pain crisis from (HbSS) patients with SCD. Plasma GlycA was measured using a proton NMR on the Vantera® Clinical Analyzer. We performed analysis comparing patients with SCD, healthy controls, and paired samples analysis. Results: The mean plasma GlycA level was lower in SCD compared with healthy controls (324.6 ± 70.4 μmol/L vs. 386.3 ± 74.6 μmol/L, P < 0.0001). Within the same patient, mean plasma GlycA during acute pain crisis was lower than steady state, although the difference was not significant (300.5 ± 36.3 μmol/L vs 314.2 ± 34.8 μmol/L, P = 0.020). Plasma GlycA correlated inversely with serum LDH (P = 0.009). Conclusion: GlycA is not a suitable biomarker of inflammation in SCD. We surmise that its signal is confounded by hemolysis leading to a depletion of haptoglobin, one of the major plasma proteins included in the composite NMR signal. Hemolysis is further exacerbated during an acute pain crisis, hence the lower GlycA levels in crisis compared to steady state. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |